Pancreatic Cancer Research

ResearcherYale Cancer CenterActive in the last 2 years

Jill Lacy

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2297-8435; OpenAlex author ID A5052643581. Sources: ClinicalTrials.gov.

Their work

Papers
19 (first author 1, last author 6)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
1
Collaborators
143
Papers, trials and grants by year

2011: 1 trial · 2012: none · 2013: 1 paper · 2014: 1 trial · 2015: 1 paper · 2016: 2 papers · 2017: 2 papers · 2018: 1 paper · 2019: 2 papers · 2020: 3 papers · 2021: 2 papers · 2022: none · 2023: 2 papers · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 19

  1. Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study. Co-author DOI 10.1093/oncolo/oyag023↗
  2. Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer: A Nonrandomized Controlled Trial. Last author DOI 10.1001/jamaoncol.2024.1575↗
  3. Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma. Co-author DOI 10.1093/oncolo/oyae155↗
  4. Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal A… Co-author DOI 10.1001/jamanetworkopen.2022.49720↗
  5. Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study P… Co-author DOI 10.1093/oncolo/oyad022↗
  6. Renalase is a novel tissue and serological biomarker in pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0250539↗
  7. Clinical outcomes of first line FOLFIRINOX vs. gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Hospital System. Last author DOI 10.21037/jgo-21-202↗
  8. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. First author DOI 10.1016/s2468-1253(19)30327-9↗
  9. A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Bor… Co-author DOI 10.1097/mpa.0000000000001592↗
  10. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcin… Co-author DOI 10.1200/jco.20.00590↗
  11. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. Co-author DOI 10.1093/jnci/djz073↗
  12. Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenoc… Co-author DOI 10.1200/jco.18.01295↗
  13. Chemoradiation after FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer. Co-author DOI 10.21037/jgo.2018.04.03↗
  14. Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.6004/jnccn.2017.0058↗
  15. EGFR Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by T790M-Mediated Resistance. Last author DOI 10.6004/jnccn.2017.0151↗
  16. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Co-author DOI 10.1016/s1470-2045(16)00172-8↗
  17. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Last author DOI 10.1038/bjc.2016.45↗
  18. Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity. Last author DOI 10.1186/s40164-015-0025-y↗
  19. FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. Last author DOI 10.1007/s12032-012-0361-2↗

Trials 2

  1. Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer Principal investigator NCT02047474↗
  2. Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer Principal investigator NCT01523457↗

Closest collaborators

The 25 strongest of 143 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael Cecchini · 5 shared papers, 2017–2024 · strength 0.65
  2. Stacey Stein · 7 shared papers, 2013–2024 · strength 0.64
  3. Kimberly L. Johung · 4 shared papers, 2018–2024 · strength 0.47
  4. Do‐Youn Oh · 3 shared papers, 2020–2026 · strength 0.46
  5. Teresa Mercade Macarulla · 3 shared papers, 2020–2026 · strength 0.46
  6. Eileen Mary O'Reilly · 2 shared papers, 2023–2026 · strength 0.38
  7. Jens Thomas Siveke · 2 shared papers, 2023–2026 · strength 0.38
  8. Charles D. Lopez · 2 shared papers, 2023–2026 · strength 0.38
  9. Gulam Abbas Manji · 2 shared papers, 2023–2026 · strength 0.38
  10. Charles H. Cha · 3 shared papers, 2016–2024 · strength 0.31
  11. Ronald R. Salem · 3 shared papers, 2016–2024 · strength 0.30
  12. Adham Adel Jurdi · 2 shared papers, 2024 · strength 0.29
  13. John W. Kunstman · 2 shared papers, 2021–2024 · strength 0.26
  14. Peter J. Hosein · 3 shared papers, 2016–2023 · strength 0.25
  15. Andrea Wang‐Gillam · 3 shared papers, 2016–2023 · strength 0.25
  16. Mariano Ponz‐Sarvisé · 1 shared paper, 2026 · strength 0.24
  17. Ben George · 1 shared paper, 2026 · strength 0.24
  18. Vincent M. Chung · 1 shared paper, 2026 · strength 0.24
  19. Angela Tatiana Alistar · 1 shared paper, 2026 · strength 0.24
  20. Howard S. Höchster · 4 shared papers, 2013–2019 · strength 0.24
  21. Anup Kasi · 2 shared papers, 2020–2024 · strength 0.23
  22. Andrew H. Ko · 2 shared papers, 2019–2023 · strength 0.20
  23. Kyu‐pyo Kim · 2 shared papers, 2019–2023 · strength 0.20
  24. Nathan Bahary · 3 shared papers, 2017–2020 · strength 0.19
  25. Philip A. Philip · 2 shared papers, 2019–2020 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.